Investigational Drug May Block Advance of Type 1 Diabetes

Share this content:

The experimental drug teplizumab shows promise for blocking the advance of type 1 diabetes in its earliest stages.

The results of a Phase 2 study show this new agent was strikingly effective over a period of two years in about half of the patients participating in the trial.

John Schieszer has the latest on the study findings in today's Medical Minute.

You must be a registered member of Renal and Urology News to post a comment.

Sign Up for Free e-newsletters